scholarly journals Dean CE, Thuras PD. Mortality and tardive dyskinesia: A long-term study using the National Death Index [abstract]. Movement Disorders 2005;20(Suppl. 10):S49

2006 ◽  
Vol 21 (3) ◽  
pp. 431-431
Author(s):  
Charles Dean ◽  
P.D. Thuras
Keyword(s):  
Tardive Dyskinesia ◽  
Movement Disorders ◽  
Index Abstract ◽  
National Death Index ◽  
Term Study ◽  
Long Term Study

scholarly journals Mortality and tardive dyskinesia: long-term study using the US National Death Index

2009 ◽  
Vol 194 (4) ◽  
pp. 360-364 ◽  
Author(s):  
Charles E. Dean ◽  
Paul D. Thuras
Keyword(s):  
Tardive Dyskinesia ◽  
Survival Time ◽  
Older Individuals ◽  
National Death Index ◽  
Term Study ◽  
Conventional Antipsychotics ◽  
Long Term Study ◽  
The Us ◽  
The Relationship

BackgroundWhether the development of tardive dyskinesia leads to an increase in mortality is still unclear.AimsTo explore the relationship between tardive dyskinesia and mortality over a 10-year period, using the National Death Index.MethodDeath certificates were obtained from the National Death Index on 1621 people repeatedly assessed for tardive dyskinesia by trained raters. Variables with the potential for influencing survival time were also investigated.ResultsTardive dyskinesia was significantly associated with an increase in mortality (P<0.001), but this association became non-significant when drug course and age were entered in the regression analysis. Those who had taken only conventional antipsychotics were twice as likely to die compared with those taking atypical agents (P<0.02). For those aged 53–65 years, conventional agents were associated with a sevenfold increase in mortality.ConclusionsOlder individuals with tardive dyskinesia treated with conventional antipsychotics appear to have a shortened survival time.

A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1998 ◽  
Vol 29 (1-2) ◽  
pp. 206 ◽  
Author(s):  
P. Wright ◽  
G.D. Tollefson ◽  
C.M. Beasley ◽  
R.N. Tamura ◽  
P.V. Tran ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Term Study ◽  
Long Term Study

An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study

2005 ◽  
Vol 77 (2-3) ◽  
pp. 129-139 ◽  
Author(s):  
Georges M. Gharabawi ◽  
Cynthia A. Bossie ◽  
Young Zhu ◽  
Lian Mao ◽  
Robert A. Lasser
Keyword(s):  
Tardive Dyskinesia ◽  
Term Study ◽  
Long Term Study ◽  
Long Acting

scholarly journals A long-term, open-label study of valbenazine for tardive dyskinesia

CNS Spectrums ◽  
2020 ◽  
pp. 1-9
Author(s):  
Jean-Pierre Lindenmayer ◽  
Cherian Verghese ◽  
Stephen R. Marder ◽  
Joshua Burke ◽  
Roland Jimenez ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Open Label ◽  
Term Study ◽  
Once Daily ◽  
Open Label Study ◽  
Patient Satisfaction Questionnaire ◽  
Label Study ◽  
Satisfaction Questionnaire ◽  
Long Term Study

Abstract Background. Individuals with tardive dyskinesia (TD) who completed a long-term study (KINECT 3 or KINECT 4) of valbenazine (40 or 80 mg/day, once-daily for up to 48 weeks followed by 4-week washout) were enrolled in a subsequent study (NCT02736955) that was primarily designed to further evaluate the long-term safety of valbenazine. Methods. Participants were initiated at 40 mg/day (following prior valbenazine washout). At week 4, dosing was escalated to 80 mg/day based on tolerability and clinical assessment of TD; reduction to 40 mg/day was allowed for tolerability. The study was planned for 72 weeks or until termination due to commercial availability of valbenazine. Assessments included the Clinical Global Impression of Severity-TD (CGIS-TD), Patient Satisfaction Questionnaire (PSQ), and treatment-emergent adverse events (TEAEs). Results. At study termination, 85.7% (138/161) of participants were still active. Four participants had reached week 60, and none reached week 72. The percentage of participants with a CGIS-TD score ≤2 (normal/not ill or borderline ill) increased from study baseline (14.5% [23/159]) to week 48 (64.3% [36/56]). At baseline, 98.8% (158/160) of participants rated their prior valbenazine experience with a PSQ score ≤2 (very satisfied or somewhat satisfied). At week 48, 98.2% (55/56) remained satisfied. Before week 4 (dose escalation), 9.4% of participants had ≥1 TEAE. After week 4, the TEAE incidence was 49.0%. No TEAE occurred in ≥5% of participants during treatment (before or after week 4). Conclusions. Valbenazine was well-tolerated and persistent improvements in TD were found in adults who received once-daily treatment for >1 year.

Sign in / Sign up

Export Citation Format

Share Document